Novotech Joins SCRS Global Impact Partner Program to Strengthen Site-CRO Collaboration in Clinical Research
February 25, 2025 – The Society for Clinical Research Sites (SCRS) proudly announces that Novotech, a leading contract research organization (CRO) providing comprehensive clinical trial solutions across global biotech markets, has joined the SCRS Global Impact Partner (GIP) program. By joining this esteemed network, Novotech will engage in SCRS working groups, conferences, and training opportunities designed to optimize site-CRO collaboration.
With over 5,000 clinical projects completed, including Phase I to IV clinical trials and bioequivalence studies, Novotech brings extensive experience across a diverse range of therapeutic areas. The company has particular expertise in oncology/immuno-oncology, infectious diseases/vaccines, neurology, and rare diseases, and offers services such as regulatory and drug development consulting, clinical monitoring, statistical analysis, pharmacovigilance, medical advisory, and more.
As a Global Impact Partner, Novotech will actively contribute to SCRS initiatives designed to enhance site sustainability, streamline study execution, and promote best practices in clinical research. Through the strategic partnership, Novotech will contribute to SCRS resources, including site engagement programs, industry insights, and leadership forums that address critical challenges in the evolving research landscape.
“Becoming a part of the SCRS Global Impact Partner Program reinforces our commitment to fostering stronger collaborations between clinical research sites and Novotech globally. This partnership enhances our ability to deliver high-quality, efficient clinical trials by supporting site development, driving operational excellence, and advancing innovation in clinical research”, states Terra Johnston, Director Regulatory Operations, Novotech.
“Joining the SCRS GIP Program represents Novotech’s mission to continuously enhance the quality of clinical trials, particularly through strengthening collaboration with research sites,” said Marcus Maleck, Vice President of Global Business Partnerships at SCRS. “Novotech’s extensive experience in biotech trials and dedication to site partnerships make them a valuable addition to our Global Impact Partner program. We are excited to collaborate with Novotech to advance initiatives that empower research sites and improve clinical trial execution on a global scale.”
SCRS Global Impact Partners are industry leaders committed to fostering stronger site partnerships and advocating for site needs within the clinical research ecosystem. For more information about SCRS and the Global Impact Partner program, visit https://scrsprograms.com.
About Novotech
About the Society for Clinical Research Sites (SCRS)
The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your success.
